The outcome of 91 @entity1 (69 males, 22 females; age range 16-82 years) with @entity189 treated in our hospital between 1971 and 1999 was evaluated. Factors that appeared to influence prognosis were assessed using the Kaplan-Meier method. The cause-specific cumulative 5-year survival rate for the entire study population was 61.2%. The 1997 International Union Against Cancer classification was used for disease staging. The 5-year survival rates were as follows: 66.7% (n = 3) for Stage I; 100% (n = 2) for Stage IIA; 90.9% (n = 11) for Stage IIB; 78.8% (n = 25) for Stage III; 53.0% (n = 29) for Stage IVA; 37.5% (n = 16) for Stage IVB; and 20.0% (n = 5) for Stage IVC. The disease-free cumulative 3-year survival rates of the @entity1 classified based on initial therapy were as follows: radiation alone, 50.0% (n = 28); combined radiotherapy and chemotherapy that included an undefined anti- @entity5 drug, 67.2% (n = 39); combined radiotherapy and chemotherapy that included @entity3003 ( @entity3003 ), 92.3% (n = 19). These results showed a statistically significant difference (p = 0.043; log-rank test). Stage IVC @entity1 were excluded from the analysis. We conclude that combined therapy, including chemotherapy with @entity3003 , is necessary for the treatment of @entity189 . In terms of radiation therapy, a field covering the bilateral cervical regions seemed to produce favorable results, even if cervical node metastasis was not confirmed by palpation at the first hospital visit. Key words: @entity3003 , chemotherapy,

XXXX of the nasopharynx: analysis of treatment results in 91 @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['CBDCA', 'carboplatin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma']
@entity189 :: (MESH:D002277,Disease) :: ['Carcinoma']
